<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03455699</url>
  </required_header>
  <id_info>
    <org_study_id>CP-1011</org_study_id>
    <nct_id>NCT03455699</nct_id>
  </id_info>
  <brief_title>VeClose Five Year Follow-Up Extension Study</brief_title>
  <official_title>Follow-up of Patients Treated in VeClose Study (Five Years)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Endovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Endovascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The VeClose Five Year Follow-up Extension Study will seek to gain additional follow-up data
      from the patients enrolled in the VeClose study (NCT01807585).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The VeClose Five Year Follow-up Extension Study will continue to assess the safety and
      efficacy of the VenaSeal Closure System for the long term effect on closure of the great
      saphenous vein by conducting a follow-up visit at five years post index procedure/enrollment
      in the VeClose study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Closure of the Target Vein at 5 years after index treatment in the VeClose study (NCT01807585).</measure>
    <time_frame>5 years</time_frame>
    <description>Complete closure is defined as Doppler ultrasound examination showing closure along entire treated target vein segment with no discrete segments of patency exceeding 5cm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Venous Clinical Severity Score (VCSS)</measure>
    <time_frame>5 years</time_frame>
    <description>Change in Venous Clinical Severity Score (VCSS) at 5 years as compared to baseline data from the VeClose study (NCT01807585).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aberdeen Varicose Vein Questionnaire (AVVQ)</measure>
    <time_frame>5 years</time_frame>
    <description>Change in Aberdeen Varicose Vein Questionnaire (AVVQ) at 5 years as compared to baseline data from the VeClose study (NCT01807585).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life survey (EQ-5D)</measure>
    <time_frame>5 years</time_frame>
    <description>Change in Quality of Life survey (EQ-5D) at 5 years as compared to baseline data from the VeClose study (NCT01807585).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CEAP classification (&quot;clinical, etiology, assessment and pathophysiology&quot;)</measure>
    <time_frame>5 years</time_frame>
    <description>Standardized measure of the degree of venous insufficiency and secondary manifestations of venous disease as measured by the treating physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with Treatment</measure>
    <time_frame>5 years</time_frame>
    <description>A brief questionnaire rating satisfaction with treatment provided and whether the subject would undergo the assigned treatment again.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AE) related to the target GSV</measure>
    <time_frame>5 years</time_frame>
    <description>AEs related to the GSV will be tabulated and reporting using the MedDRA dictionary, version 16.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjunctive procedures performed on the study limb</measure>
    <time_frame>5 years</time_frame>
    <description>Details of adjunctive procedures performed on the study limb will be captured on Case Report Forms (CRFs)</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">205</enrollment>
  <condition>Great Saphenous Vein (GSV) With Venous Reflux Disease</condition>
  <arm_group>
    <arm_group_label>Experimental: VenaSeal SCS</arm_group_label>
    <description>Endovenous delivery of VenaSeal Adhesive (VA) to a target site in diseased great saphenous veins (GSV). The VA is dispensed in small amounts with each pull of the trigger equaling 0.10 cc. Subjects were randomized in a 1:1 ratio to either VenaSeal SCS or to RFA at the time of enrollment into the VeClose study (NCT01807585).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator: RFA</arm_group_label>
    <description>Endovenous insertion of the ClosureFast radiofrequency ablation (RFA) catheter into a target site in diseased great saphenous veins (GSV). Heat is applied to the target vein using radiofrequency energy to ablate the target vein. Subjects were randomized in a 1:1 ratio to either VenaSeal SCS or to RFA at the time of enrollment into the VeClose study (NCT01807585).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: Roll-in (VenaSeal SCS)</arm_group_label>
    <description>Prior to initiation of the randomized cohort at each site for the VeClose study (NCT01807585), a non-randomized cohort of 2 subjects per site (roll-in phase) were enrolled and treated with VenaSeal SCS with endovenous delivery of VenaSeal Adhesive (VA) to a target site in diseased great saphenous veins (GSV). The VA is dispensed in small amounts with each pull of the trigger equaling 0.10 cc.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VenaSeal SCS</intervention_name>
    <description>Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.</description>
    <arm_group_label>Experimental: VenaSeal SCS</arm_group_label>
    <other_name>VenaSeal Sapheon Closure System</other_name>
    <other_name>VSCS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ClosureFast Radiofrequency Ablation (RFA)</intervention_name>
    <description>Radiofrequency thermal ablation of the GSV using the Covidien ClosureFast system.</description>
    <arm_group_label>Active Comparator: RFA</arm_group_label>
    <other_name>ClosureFast</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Roll-In (VenaSeal SCS)</intervention_name>
    <description>Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.</description>
    <arm_group_label>Experimental: Roll-in (VenaSeal SCS)</arm_group_label>
    <other_name>VenaSeal Sapheon Closure System</other_name>
    <other_name>VSCS</other_name>
    <other_name>Roll-in</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects currently enrolled in both arms of the VeClose Study (NCT01807585) will be
        assessed for eligibility to enroll in the VeClose Five Year Follow-up Extension Study. All
        subjects must meet the inclusion criteria and must not meet the exclusion criteria.
        Assessment of eligibility is based on data available to the investigator at the time of
        subject enrollment. The subject will be considered to be enrolled in the VeClose Five Year
        Follow-up Extension Study after the informed consent is signed/dated and all of the study
        eligibility criteria have been met.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Enrolled in the VeClose study.

          2. Able and willing to complete the required 5 year study visit including Duplex
             ultrasound exam.

          3. Able and willing to provide written informed consent prior to study specific data
             collection.

        Exclusion Criteria:

        1. Withdrew consent from the VeClose study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nick Morrison, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Morrison Vein Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sr. Clinical Program Manager, EV Clinical</last_name>
    <phone>707-525-0111</phone>
    <email>sue.s.kim@medtronic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sr. Clinical Research Specialist, EV Clinical</last_name>
    <phone>707-525-0111</phone>
    <email>diane.cacho@medtronic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Morrison Vein Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85255</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janice Beans</last_name>
      <phone>480-775-8460</phone>
    </contact>
    <investigator>
      <last_name>Nick Morrison, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GBK Cosmetic Laser Dermatology</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabella Guiha</last_name>
      <phone>858-657-1002</phone>
    </contact>
    <investigator>
      <last_name>Mitchel Goldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiology Imaging Associates (RIA)</name>
      <address>
        <city>Greenwood Village</city>
        <state>Colorado</state>
        <zip>80111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Talley</last_name>
      <phone>720-493-3403</phone>
    </contact>
    <investigator>
      <last_name>E. Brooke Spencer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prairie Education &amp; Research Cooperative</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Diefenback, LPN</last_name>
      <phone>217-492-9100</phone>
    </contact>
    <investigator>
      <last_name>Gabor Matos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Laser Skin &amp; Vein Institute</name>
      <address>
        <city>Hunt Valley</city>
        <state>Maryland</state>
        <zip>21030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristi Myers, BSN</last_name>
      <phone>410-666-2839</phone>
    </contact>
    <investigator>
      <last_name>Robert Weiss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vein Institute of Buffalo</name>
      <address>
        <city>North Tonawanda</city>
        <state>New York</state>
        <zip>14120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristina Morrison</last_name>
      <phone>716-877-7000</phone>
    </contact>
    <investigator>
      <last_name>Michael Vasquez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inovia Vein Speciality Center</name>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <zip>97701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noura Sall, BSN</last_name>
      <phone>541-382-8346</phone>
    </contact>
    <investigator>
      <last_name>Andrew Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sentara Vascular Specialists</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23452</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Holm, RN</last_name>
    </contact>
    <investigator>
      <last_name>Scott McEnroe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lake Washington Vascular</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krissa Gunderson, BS</last_name>
      <phone>425-732-5958</phone>
    </contact>
    <investigator>
      <last_name>Kathleen Gibson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Morrison N, Gibson K, Vasquez M, Weiss R, Cher D, Madsen M, Jones A. VeClose trial 12-month outcomes of cyanoacrylate closure versus radiofrequency ablation for incompetent great saphenous veins. J Vasc Surg Venous Lymphat Disord. 2017 May;5(3):321-330. doi: 10.1016/j.jvsv.2016.12.005. Epub 2017 Mar 6.</citation>
    <PMID>28411697</PMID>
  </reference>
  <reference>
    <citation>Kolluri R, Gibson K, Cher D, Madsen M, Weiss R, Morrison N. Roll-in phase analysis of clinical study of cyanoacrylate closure for incompetent great saphenous veins. J Vasc Surg Venous Lymphat Disord. 2016 Oct;4(4):407-15. doi: 10.1016/j.jvsv.2016.06.017. Epub 2016 Aug 8.</citation>
    <PMID>27638993</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2018</study_first_submitted>
  <study_first_submitted_qc>February 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2018</study_first_posted>
  <last_update_submitted>February 28, 2018</last_update_submitted>
  <last_update_submitted_qc>February 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GSV</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

